Product Images Capecitabine

This is a description of a medication called Capecitabine Tablets, USP, which contains 150mg of capecitabine. The usual dose and storage instructions are provided but further information is available in the package insert. The medicine should be kept at controlled room temperature and dispensed in tight containers as defined in USP/NF. It was manufactured by MSN Laboratories Private Limited in India and distributed by MSN Pharmaceuticals Inc. in Piscataway, NJ. The product is available in 1000 tablets and is only available with a prescription. A Patient Information Leaflet should be given to each patient by the pharmacist.*

This is a medication called Capecitabine Tablets, USP, which contains 150mg of capecitabine per film-coated tablet. It is advised to store the medication at 25°C (77°F) with excursions permitted between 15°C-30°C (59°F-86°F). The medication should be kept tightly closed and dispensed in tight containers as defined in USP/NF. It is manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by MSN Pharmaceuticals Inc. in Piscataway, NJ, USA. The package comes with a Patient Information Leaflet for each patient.*

Capecitabine Tablets, USP containing 500mg capeditabine, manufactured by MSN Laboratories Private Limited, Telangana, India. Dosage and other important prescribing information can be found in the accompanying insert. The tablets should be stored tightly closed at controlled room temperature. Dispense in tight containers as per USP/NF guidelines. The drug should only be dispensed with a Patient Information Leaflet. NDC: 69539-020-99.*

This text describes a medication in the form of a film-coated tablet. The tablet contains 500 mg of capecitabine, and the recommended dosage and other information can be found in the accompanying insert. The tablet should be kept tightly closed and dispensed in containers defined by the USP/NF. The medication is manufactured by MSN Laboratories Private Limited and distributed by MSN Pharmaceuticals Inc. The text also includes a lot number and issue date.*

This appears to be a survival analysis table comparing the effectiveness of two treatments (5FU+LEUCOVORIN and CAPECITABINE) over different periods of time in terms of n at risk and months since randomization.*

This appears to be a survival graph that compares the effectiveness of two treatments, "5-FU + LEUCOVORIN" and "CAPECITABINE", over a period of time, with "n at risk" indicating the number of participants who were still being monitored at each time-point. The use of leucovorin in combination with 5-FU (fluorouracil) is a standard treatment for colon and rectal cancer. Capecitabine is an oral chemotherapy drug used to treat the same cancers. However, without more context or details about the study, it is not possible to make further conclusions.*

This appears to be a graph or a table, showing the estimated probabilities for different treatments or interventions, alongside the time elapsed. However, without more context or information, it's not possible to give a clear description or interpretation of the data.*

The text appears to be a chemical structure with various elements and compounds. It's likely related to biochemistry or organic chemistry. Specifically, it appears to show the structures of Capecitabine, 5-DFCR, 5-DFUR, and 5-FU. There are also references to enzymes such as Cyd deaminase and dThdPase. It is not possible to generate a useful description as there is no context provided.*